We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Minaris

News List

Minaris and bluebird bio Enter Manufacturing Pact contractpharma
July 23, 2021
The CDMO will be the commercial manufacturer in Europe for Skysona, bluebird bio’s gene therapy for CALD.
Minaris Will Be the Commercial Manufacturer in Europe for Skysona™, bluebird bio’s Gene Therapy for CALD b3cnewswire
July 22, 2021
Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for Skysona™ (elivaldogene autotemcel, Lenti-D™), a
MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement contractpharma
February 23, 2021
MaxiVAX SA and Minaris Regenerative Medicine GmbH have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.
Minaris Invests $64.5M to Expand Cell and Gene Mfg. Facilities contractpharma
November 04, 2020
New buildings near Munich, Germany and Yokohama, Japan will more than double capacity for commercial manufacturing of regenerative medicines.